Galapagos NV Overview
Pro stress-test →Galapagos NV is a Belgian biotechnology company specializing in the discovery and development of innovative small molecule medicines and cell therapies targeting diseases with high unmet medical needs, particularly in oncology and immunology. The company has a diversified pipeline spanning inflammatory diseases, fibrosis, and advanced cell therapy modalities, with a transformational focus on decentralized CAR-T manufacturing.
Strategic Profile
Pro stress-test →Galapagos differentiates itself through integrated R&D capabilities combining small molecule drug discovery with cutting-edge cell therapy platforms and decentralized manufacturing networks. The company has divested non-core assets (including Jyseleca to Alfasigma) and announced plans to wind down its cell therapy business to focus on business development and pipeline innovation, while maintaining strategic partnerships with Gilead Sciences and AbbVie to enhance its therapeutic portfolio.
Competitive Landscape
Pro stress-test →Galapagos competes in crowded oncology and immunology markets against established players like Moderna, Kite Pharma (Gilead), and Juno Therapeutics (Bristol Myers Squibb) in CAR-T therapies, plus numerous small molecule developers in inflammation and fibrosis. Key differentiators include its decentralized cell manufacturing platform and access to Gilead's distribution infrastructure.
Industry Context
Galapagos NV operates in Biotechnology - Small Molecule & Cell Therapy Development.
Key facts
Founded: 1999 · Headquarters: Mechelen, Belgium · Employees: ~500-600 · Revenue: Limited (post-Jyseleca divestiture) · Market cap: ~$1.2B EUR